Clinical Trial Update: Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]

View source ↗

Summary

Phase 3 trial update describes switching study participants with atypical hemolytic uremic syndrome from anti-C5 antibody therapy to iptacopan, assessing effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 3 | Status: RECRUITING